Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Titel:
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Auteur:
Amaria, Rodabe N Prieto, Peter A Tetzlaff, Michael T Reuben, Alexandre Andrews, Miles C Ross, Merrick I Glitza, Isabella C Cormier, Janice Hwu, Wen-Jen Tawbi, Hussein A Patel, Sapna P Lee, Jeffrey E Gershenwald, Jeffrey E Spencer, Christine N Gopalakrishnan, Vancheswaran Bassett, Roland Simpson, Lauren Mouton, Rosalind Hudgens, Courtney W Zhao, Li Zhu, Haifeng Cooper, Zachary A Wani, Khalida Lazar, Alexander Hwu, Patrick Diab, Adi Wong, Michael K McQuade, Jennifer L Royal, Richard Lucci, Anthony Burton, Elizabeth M Reddy, Sangeetha Sharma, Padmanee Allison, James Futreal, Phillip A Woodman, Scott E Davies, Michael A Wargo, Jennifer A